A live archive of receipt-bound excerpts from company earnings calls. No generated thesis, no recommendation — just the recorded language, its source coordinates, and a direct path into the ticker dossier or live Terminal.来自公司财报电话会的可追溯摘录档案。没有生成式投资结论，也没有推荐——只有原始表述、来源坐标，以及进入个股档案或实时终端的直接入口。
Start free in Terminal免费开始使用终端649 verified call records份已核验电话会记录 · 7788 exact facts条精确事实 · 2026-10-26 → 2026-11-01
Browse the full archive page by page. Search on this page by ticker, period, category, or speaker; every card preview is a verbatim call excerpt.分页浏览完整档案。在本页按代码、期间、分类或发言人搜索；每张卡片预览均为电话会原文摘录。
Showing records 5185–5280 of 6702.显示第 5185–5280 条，共 6702 条。
“Just a quick one on the factors that would see you land towards the top or bottom of the range for guidance, both on sales and operating profit, given I guess you've got 1 quarter to go on organic sales and obviously a whole half for operating profit.”
“In terms of guidance, we still expect our 2026 diluted net income per common share to be between -$0.20 and -$0.14.”
“The impact purely from a, you know, winter storm perspective is roughly about 1% on a year-over-year growth perspective from a GOV basis.”
“In our Health Care Benefits segment, we now expect full year adjusted operating income to be in a range of approximately $4 billion-$4.34 billion, an increase of $420 million relative to our prior guidance, reflecting the favorable prior year development that we experienced in the first quarter.”
“If we are gonna fill a 1 million barrel a day pipeline to the West Coast, it's gotta come with growth, and that growth has to come from capital, and that capital has to be, you know, competitively advantaged vis-a-vis, you know, where else it can go.”
“Year-over-year, Corteva delivered a 21% increase in Q1 EBITDA and over 200 basis points of margin expansion driven by our core portfolio, our growth platforms, and focused cost execution.”
“Excluding DecisionDx-SCC and IDgenetix revenue, our revenue growth for the first quarter of 2026 is approximately 42% compared to the first quarter of 2025, highlighted by double-digit year-over-year test report volume growth for both DecisionDx-Melanoma and TissueCypher.”
“For the full fiscal year 2026, Cirrus Logic delivered record revenue of $2 billion, up 5% from the prior year, driven by demand for components shipping into smartphones as well as higher PC sales.”
“We expect adjusted EBITDA between $67 million and $71 million, reflecting lower top line, continued high ROI investments in agentic AI and growth areas, annualized employee costs, and our annual promotion cycle and foreign exchange rate headwinds on our European cost base.”
“Just philosophically on guidance, when you guys provide guidance, should we think of that as a P 50 with a little bit of risking, so call it P 45, P 55 range?”
“As expected, year-over-year, our gross margin rate was pressured by tariffs, a gross incremental impact of roughly $50 million in the quarter.”
“Separately, you may have noticed that we increased our target cash gross profit range for the CoreWeave contract to 80%-85%, up from our original target of 75%-80%.”
“Healthcare Solutions EBIT growth, excluding OneOncology and the loss of an oncology customer, Jim, you also mentioned there's a 1% headwind from COVID-19 and another 1% headwind from weather.”
“In particular, we expect 800G revenue to grow year-over-year in calendar 2026, while 1.6T transceivers ramp rapidly through the balance of this calendar year and into next year as a broad range of customers adopt 1.6T.”
“5.11 Tactical delivered solid margin performance and strong cash flow in the quarter, despite some modest top-line pressure.”
“Entering 2026, our first quarter results demonstrate how market-leading growth, GAAP net income profitability, and full risk can scale together in Medicare Advantage.”
“Field service revenue grew 7% in the quarter as we responded to a steady stream of customer emergency events across the U.S., including a large-scale event that generated approximately $10 million in revenue.”
“Gross profit margin was 32.5%, down from 34.4% in the prior year's second quarter and down slightly from 33.2% in the first quarter of fiscal 2026, mainly due to lower sales volume.”
“We're continuing to execute on multiple dimensions of growth with 19% growth in active members, 5% growth in average revenue per active member, or RPAM, and a 9 percentage point improvement in transaction margin in Q1.”
“I'll note that we expect our second quarter interest expense to be higher, however, based on an additional day in the second quarter, a full quarter of our current revolver balance, which includes net borrowings from our inpatient rehabilitation facility acquisition in February, and the expiration in late March of $75 million of interest rate hedges.”
“Net sales were $906 million, a 9% year-over-year increase driven by growth across both segments and reflecting solid underlying demand, the anticipated shift of shipments from the first quarter into the second, and the benefits of actions we've taken to strengthen the business.”
“Net sales were $906 million, a 9% year-over-year increase driven by growth across both segments and reflecting solid underlying demand, the anticipated shift of shipments from the first quarter into the second, and the benefits of actions we've taken to strengthen the business.”
“Is there any color or commentary you can help us understand, like composition of the backlog, either by category, duration, and what the underlying sort of margin dynamics of said products within the backlog looks like, so we can think about timing of how that backlog fills into the second half and maybe into calendar 2027 and what the potential margin impacts might look like?”
“It is worth noting that some demand and associated sales, having about a $10 million impact on adjusted EBITDA, was pulled forward into the first quarter due to timing, which modestly tempers the sequential progression we would have otherwise expected and added strength to our first quarter TSS performance.”
“The segment's 3% higher volumes as compared to the prior year were more than offset by lower gross profit per ton, driven by calendar year 2026 customer agreement outcomes and increased competitive intensity in Asia Pacific.”
“We expect advertising and other revenues to grow 11%-14% year-over-year, reflecting the ongoing benefits of diversification across both supply and demand on our platform, even as brands continue to navigate a dynamic macro environment.”
“A more substantial improvement in reported gross margin was frustrated by the flow-through of Q4 2025 inventory produced during a period of particularly low volume and overhead absorption, obscuring progress we are making on COGS, specifically conversion rates.”
“During the first quarter, revenues increased 3% year-over-year, driven primarily by Disdero Lumber Company specialty sales and higher volumes in our key specialty product categories, which helped offset ongoing pricing pressure in specialty and structural products and margin pressure in specialty products.”
“For 2026, we expect net revenue to be in the range of $520 million to $540 million, and we expect to report Adjusted EBITDA margin between 17.25% and 17.75%.”
“We believe we'll get to double-digit growth in the second half and even for 2026 overall, as we gain additional share in BGS and see the impact from the investments we're making across Ultrasonics, trained surgeons, expand our sales force, and enhance awareness of our differentiated technology and clinical and economic value.”
“This came in $70 million above the high end of our original guidance, enabling us to fund accelerated investments into our sales force, which will further drive sustained, profitable top-line growth.”
“With our Q1 same-shop sales results and performance into Q2, we now expect full-year system same-shop sales growth of 4%-6%.”
“With the easing of tariffs and foreign exchange headwinds we experienced in the second quarter of 2026, we expect a meaningful year-over-year step up in non-GAAP operating margin and non-GAAP EPS, with continued improvements in both metrics expected in the second half of the year.”
“Fleming's comp sales were up 80 basis points, with traffic down 290 basis points, reflects the seventh consecutive quarter with positive comp sales growth.”
“While the faster growth of our oncology business can influence margins, as oncology currently has lower margins due to lower volume scale and prior to Medicare coverage of Response, we expect to maintain strong overall gross margins above 70%.”
“Starting on the left at $49.2 million, the impact of the bus segment gross profit in total was $1.7 million, split between volume and pricing effects, net of material cost increases of $4.3 million and year-over-year healthcare cost increases and lower overhead absorption of $2.6 million.”
“is still an important contributor towards our peak, but we are the vast majority, well over 90% of our revenue now comes from the U.S., and we expect it to be that way even as the brand grows towards $1 billion.”
“On a standalone basis for 2026, we expect EBITDA margins to expand by 30 to 50 basis points as we shift revenue to these higher margin services and drive cost productivity across our operations.”
“The decline was primarily driven by 120 basis points of pressure in Multiomics from lower volumes and gross margin compression, as well as down 360 basis points from investments in sales, product marketing and R&D to support future growth.”
“We currently expect to generate a majority of our 2026 revenue through operations between customer facilities, reflecting our continued focus on increasing commercial value.”
“The backlog and Infrastructure Solutions segment increased $37 million or 13%, primarily due to increases in asphalt plants, mobile paving, and forestry equipment, and a $17 million contribution from the newly acquired CWMF.”
“Based on our latest assessment of our customers' project sequencing and/or delivery preferences, we expect revenue in the second quarter in the range of $300 million-$320 million.”
“The investments we're making and the efforts we're taking to advance our initiatives across these three pillars are laying groundwork for further ZORYVE sales inflection and operating leverage expansion in 2027 and far beyond, as well as positioning us to sustain growth for the long term, and most importantly, expanding our impact on individuals living with chronic inflammatory dermatoses.”
“Overall, we're encouraged by the strong start to 2026, which keeps us on pace to achieve our full year 2026 adjusted EBITDA guidance range of between $865 million and $950 million, which we expect will translate into meaningful free cash flow generation for the year.”
“However, we are maintaining our outlook of $1 billion while we pursue supply chain capacity, and we still expect the first revenues from production shipped sales to land in the fourth quarter of this fiscal year.”
“Collectively, these actions helped drive first quarter total surgery growth of 1.2% year-over-year, which is a 100 basis point improvement over full year 2025 growth.”
“Turning to our outlook for the second quarter of 2026, we expect revenue between $1.915 billion and $1.945 billion, representing 52%-55% year-over-year growth or 4%-6% sequentially.”
“Based on what we're seeing for the first quarter and what we see in the pipeline for the year, we're reaffirming our 26% outlook of 20% FRE growth and 10% SRE growth, and the business trends continue to be highly favorable.”
“Looking across calendar 2026, we expect a dynamic environment with some uncertainty in consumer-related demand, particularly given the impact of memory pricing on end markets such as PCs and smartphones.”
“When we think about our $5 billion revenue target, one way to do it is to get 7% of the market at a 10% take rate.”
“We expect fiscal 2026 free cash flow of $1.5 billion-$1.6 billion, including the impact of our decision to hold more inventory at higher costs.”
“This will allow us to recapture lost production when crush margins are typically stronger and keep us on track with our goal to increase total 2026 alcohol volumes and prioritize product mix that delivers a premium to domestic renewable fuel.”
“I'll now turn the call over to Keith Meier to speak to the underlying growth levers of our business, including our updated 2026 outlook.”
“Utilizing the midpoint of guidance ranges provided within our earnings release, we now expect revenue of approximately $5.7 billion, medical margin of approximately $375 million in 2026, and Adjusted EBITDA of approximately $25 million.”
“This includes achieving a new record revenue quarter of $6.3 million in Q1, which represents an increase of around 90% year-over-year, driven by scaling sensor shipments across multiple markets and progression on development milestones for major customers.”
“As Dave mentioned, we are reiterating our prior 2026 guidance, including flat to low single-digit revenue growth, adjusted EBITDA flat to down mid-single digits, adjusted unlevered free cash flow of $250 million-$235 million, and net free cash flow conversion of approximately 25% of adjusted EBITDA, excluding incremental costs related to our debt extension.”
“Turning to Q2 EBITDA performance, adjusted EBITDA of $223 million included approximately $8 million of temporary customer-driven production inefficiencies, which we expect to recover in future periods, and $11 million of launch expense, which supports future growth in our expanding program portfolio.”
“We grew adjusted net income by 22% year over year, expanded corporate gross margins to 71%, and generated approximately $58 million of operating cash flow during the quarter.”
“Despite these headwinds, Q1 revenue was $204 million and grew 12% year-over-year.”
“For full-year 2026, we continue to anticipate operating expenses in the range of $215 million-$220 million, excluding any reorganization costs as we prudently manage our expense base, balancing our ongoing focus on driving further efficiencies across the business, with continuing to invest in our growth initiatives.”
“Importantly, we saw double-digit referral growth in the first quarter and robust demand growth at 8% even prior to the expected impact of the recent sales force expansion.”
“Our strategic reserve grew from 5,401 Bitcoin as of December 31st, 2025, to 7,021 Bitcoin at quarter end, an increase of approximately 1,620 Bitcoin in a single quarter, or roughly 30% growth in 90 days.”
“In the near term, those are reflected on slide 15, they are the full year impact of our Drive 25 cost efficiency initiative, increasing customer wallet share at higher margins to continue to internationalize services and technologies acquired in previous acquisitions, spreading those into new geographic areas.”
“While it represents a moderate portion of our business today, we have continued to see strong sequential growth in AI applications with approximately 30% sequential growth from Q2 to Q3 and increasing customer engagement, which gives us confidence in the long-term trajectory of this opportunity.”
“Importantly, as we previously discussed, the balance sheet leverage tightness is primarily an issue for 2026 and 2027 before the historic earnings growth we expect in 2028 and beyond.”
“PEM delivered net sales of $1.7 billion and EBITDA of $36 million on 3% sequential volume growth, excluding the impact to volumes from our 2025 plant shutdowns.”
“To meet growing demand for the technical and maintenance expertise of our engine shops, which contributed revenue of $10 million in the first quarter, exclusive of intercompany sales, and to enhance our vertical integration, we continue to invest in deepening our in-house technical capabilities.”
“We are also raising our 2026 free cash flow margin outlook by 100 basis points to approximately 20%.”
“We're on track to deliver results in line with our 2026 earnings guidance of $5.51 to $5.61 a share.”
“Given our strong first quarter results, updated FX assumptions, and the prudence embedded in our second half outlook, we are raising our full year adjusted EPS guidance by $0.10 to $14.40 per share to $14.60 per share, reflecting growth of 10%-11%.”
“Free cash flow for the quarter was $12 million after $18.7 million of development capital expenditures net of divestitures.”
“We continue to target approximately 25% organic revenue growth, gross margins in the range of 30%-35% and mid-teens adjusted EBITDA margins excluding Starlab, with low teens free cash flow margins excluding Starlab as the platform continues to scale.”
“Importantly, this increased production outlook represents over 5% organic growth relative to our pro forma 2025 exit rate.”
“As previously indicated, we expect there to be significant earnings growth in 2027 as the positive impact from PENN 1 and PENN 2 lease-up takes effect, as well as the positive impact of the recent acquisition of Park Avenue Plaza.”
“Regionally, performance was strong in the Americas, where adjusted growth was 6% year-over-year, supported by higher volumes on key programs and new business wins.”
“Turning to our 2026 outlook, we are raising full-year total revenue guidance to $582 million-$592 million, representing 13%-14% year-over-year growth compared to our prior range of $570 million-$582 million.”
“The increase in gas-adjusted gross margin was driven by higher rates in customer growth of $10.3 million and the favorable effects of colder winter weather in 2026 of $0.9 million.”
“We continue to maintain our full-year adjusted EBITDA range of $778 million-$100 million, distributable cash flow range of $480 million-$510 million, maintenance capital range of $60 million-$70 million, and expansion capital range of $230 million-$250 million.”
“Maybe just as a follow-up, sort of applying maybe the same rubric to kind of the medium term, you know, the three-year guidance, I mean, 35% revenue CAGR is obviously significant, and margins going from 21% to 25% is material as well.”
“Adjusted EBITDA for Risk and Compliance Software was $19 million in the quarter, up 26.7% year-over-year, with adjusted EBITDA margin expanding 460 basis points to 29.2%.”
“Turning to the second quarter, our guidance reflects RASM growth of greater than 20% and stage-adjusted RASM up high teens year-over-year, supported by durable demand trends and lower competitive capacity on Frontier routes.”
“We are reaffirming our full year 2026 outlook for organic growth in a range of 7.5%-8%, including approximately 9.5% for the Big Three segments, and for our margins to rise by 100 basis points year-over-year to approximately 40%.”
“The gross margin impact is comprised of approximately $11 million due to the lost volume from the shutdown and approximately $6 million from elevated labor, freight, and expediting costs during the post-implementation ramp-up.”
“transplant ecosystem and at the macro level, we are reiterating our revenue guidance for the full year 2026 between $727 million-$757 million, representing a 20%-25% growth over full year 2025.”
“These ranges do not include any contribution from the pending Cornerstone acquisition, and we expect to provide an update to 2026 guidance after closing the transaction.”
“Jim, as we layer the Merck and Gilead wins on top of the $350 million of TCV that was already earmarked for revenue in 2026, how much visibility and confidence do you have in hitting the implied $410 million of data revenue guidance, and what are the potential levers for upside there?”
“Looking to the remainder of 2026, first quarter 2026 revenue plus firm backlog and options for the legacy Tidewater fleet represents $1.1 billion of revenue for the full year, representing approximately 84% of the midpoint of our legacy Tidewater 2026 revenue guidance.”
“Non-GAAP operating margin also improved significantly by more than 500 basis points year-over-year, driven by higher recurring revenue and a continued focus on operating leverage to deliver profitable growth.”
“Despite the workers' compensation headwind I mentioned earlier, PeopleReady segment profit margin was up 10 basis points, driven by targeted cost actions to deliver efficiencies and improve profitability.”
“While growth remains healthy, we have seen a modest slowdown over the past year, particularly in Southern Nevada, which we view as somewhat localized and timing-related rather than indicative of a change in long-term demand trends, which, as Karen noted, project population growth rates in both Arizona and Nevada to trend near 5% from 2026 to 2031, according to S&P.”
“We posted revenue of $944 million, roughly $20 million above the high end of our guidance range, delivered earnings per share of $1.15, $0.05 above the high end of our guidance range, and paid $107 million in quarterly dividends.”
“Lastly, we are pleased to confirm our 2026 guidance, which anticipates significant sales growth and even stronger growth in adjusted EBITDA within a challenging macro environment and where pool starts will be about flat from last year.”
“Despite typical first quarter headwinds, Qelbree's growth continues to be solid and is coming from both patient populations, with adult prescription growth of 27% and pediatric prescription growth of 15%.”
“We're increasing our guidance ranges for 2026 as follows: Revenue of $3.7 billion-$3.8 billion, which at the midpoint is a 20% increase over previous guidance and represents more than 50% growth over 2025.”
“Most recently, I served as CEO of Tactile Medical, where we grew revenue from $187 million to approximately $300 million.”
“Looking ahead, we expect our ongoing free cash flow, combined with proceeds from the sale of Çöpler before the end of the third quarter of 2026, will further strengthen the balance sheet and enhance our ability to continue to allocate capital with discipline while prioritizing high return growth opportunities and long-term value creation.”
Try a ticker, period, category, or a call speaker.请尝试代码、期间、分类或电话会发言人。
This is a transcript-only, historically incomplete publication. Releases, filings, slides, consensus and price reaction are visibly marked as not joined; lower-evidence packets remain held instead of being inferred.这是仅基于电话会文本且历史覆盖尚不完整的发布。新闻稿、披露文件、演示材料、一致预期和股价反应均明确标注为未接入；证据不足的数据包会被暂缓，而非由推断补齐。